2018
DOI: 10.1590/s0103-73312018280102
|View full text |Cite
|
Sign up to set email alerts
|

Os medicamentos e tecnologias farmacêuticas como uma questão estratégica para a viabilidade do Sistema Único de Saúde

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
2
0
1

Year Published

2018
2018
2022
2022

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(3 citation statements)
references
References 3 publications
(2 reference statements)
0
2
0
1
Order By: Relevance
“…Among the strategies indicated as indispensably necessary are the expansion of investments and regulation for Brazilian scientific and technological development, for the needs of the Brazilian population and health services. The high costs and prices of medicines and other technologies, regu-latory barriers and intellectual property 12,[18][19][20][21] are themes that were presented in the presentations and discussions, reaffirming the importance and the opportunity of the regional seminars. Also, about financing, several proposals for the direction of investments, with prioritization for research on neglected and endemic diseases and for qualification of services.…”
Section: Discussionmentioning
confidence: 96%
“…Among the strategies indicated as indispensably necessary are the expansion of investments and regulation for Brazilian scientific and technological development, for the needs of the Brazilian population and health services. The high costs and prices of medicines and other technologies, regu-latory barriers and intellectual property 12,[18][19][20][21] are themes that were presented in the presentations and discussions, reaffirming the importance and the opportunity of the regional seminars. Also, about financing, several proposals for the direction of investments, with prioritization for research on neglected and endemic diseases and for qualification of services.…”
Section: Discussionmentioning
confidence: 96%
“…Outro exemplo de sobreposição do direito à saúde por direitos comerciais está na crescente financeirização do setor biofarmacêutico, fusões e aquisições de startups que, com o tempo, vão ganhando valor de mercado, o que influencia a falta de detalhamento dos custos de P&D do produto. Essa falta de transparência dá às empresas biofarmacêuticas vantagem nas negociações de preços e competitividade, especialmente aquelas com tecnologias de monopólio 34 .…”
Section: Essas Iniciativas De Governança Global Da Saúde Estão Servin...unclassified
“…Leite et al 52 emphasize the need to increase the budget for health funding and the repeal of CA nº 95/2016. Coupled with this, the uncertain future scenario for the funding of research, whether basic or applied, the promotion of public production of medicines and the induction of the Economic-Industrial Health Care Complex, as well as the impact on the capacity of the State to incorporate or not new technologies and the continuous provision of those already incorporated 35,41,53 .…”
Section: Perspectives and Challenges For Translational Health Researcmentioning
confidence: 99%